Aura Biosciences Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Maybe overview recent milestones and upcoming milestones, and walk us through the rationale for focusing on ocular oncology.
Yes. I have been with the company for six months, just about. It has been a really fantastic time of really excellent execution on the part of the team. We are developing our product candidate, bel-sar, for the treatment of early choroidal melanoma. We completed enrollment in our pivotal study in May of this year, and we are on track for top-line efficacy data in the second half of 2027. This is a very exciting time for the company. The platform technology that is the basis for the product candidate shows really excellent promise against really any solid tumor. Some of the foundational work from John Schiller's lab at the NIH shows that across 140 different cell lines of different solid tumor types, bel-sar has excellent potency and selectivity.
If you are a big visionary, like the founder of the company, Elisabet de los Pinos, you see the potential for using this in a range of solid tumors. A few years ago, the decision was made to move into the NMIBC, the bladder cancer space, in parallel with the work that the company was already doing in ocular oncology. When I came into the company, my history and background is primarily in late-stage and commercial phase rare disease companies. I looked at the opportunity, as we will talk about, in early choroidal melanoma and saw incredible potential for delivering really transformative value for patients who have a very poor set of choices when they are given this diagnosis, and consequently, create a lot of value for shareholders.
In my experience, the more things you are trying to do at the same time, the more execution suffers a little bit. If you want to be the best in the world, you kind of have to go all in on it. We announced preliminary data from the NMIBC program in the summer. It actually looked quite encouraging, which provides a nice read-through into the ocular oncology space. We decided to put that program, finish the study, but deprioritize it and go all in on building the world's preeminent ocular oncology company around bel-sar, with the initial indication in early choroidal melanoma, but also with earlier stage programs in metastases to the choroid from other solid tumors and ocular surface cancers, which, if they go forward, have the opportunity to really be a first-in-class frontline therapy for a really devastating set of diseases.
Mm-hmm. We typically see in oncology that companies go for a late-line label behind the competition, and then they work their way up to earlier line settings. It sounds like Aura is doing things a little bit differently. It would be great to frame the opportunity and competitive positioning here.
Yeah. First, it's important to understand that when we're talking about choroidal melanoma, it is more or less synonymous with uveal melanoma. 95% of uveal tumors appear in the choroid. Actually, all of the drug development that has been done in the uveal melanomas space to date follows the model that you suggested. There has been a fair bit of drug innovation in the metastatic setting, a little bit of innovation in the large to medium-sized tumors. But in early choroidal melanoma, where the vast majority of these patients sit, these tumors are generally caught early, there's been no meaningful innovation. The profile of bel-sar is such, it's local therapy that is delivered directly to the choroid. The mechanism of action of bel-sar is exquisitely selective for tumor cells. The cytotoxic activity only occurs with light activation.
We have a profile that really lends itself to treating early, which all the data in the field shows leads to the best outcomes. When we think about the competitive landscape of uveal melanoma, there is no competition in the early choroidal melanoma space. We are the only program, to our knowledge, that is exploring treatment of the early stages of the disease. Hopefully, these patients never get to later stage disease if we're successful.
How significant is the unmet need, and what kind of options do diagnosed patients have today?
Yeah. The unmet need is significant. This is a really devastating diagnosis to get. The current treatment options are, you have a melanoma growing in your eye. Number 1, we can leave it alone and roll the dice, and all the data show that the bigger these tumors get, the larger the risk of metastatic disease. Number 2, we can treat with radiotherapy, either plaque radiotherapy or proton radiotherapy. It will stop the tumor from growing further, which is considered a complete local cure, but you put the majority of patients on an irreversible path to blindness in the treated eye.
The third choice is we can take the eyeball out altogether. We can do enucleation. So, it's a really difficult decision to make. Do I trade increased risk of advancing disease for preserving my vision, or do I treat the tumor early but know that I'm going to blind this patient?
The unmet need, I think, is unarguable. The value proposition with bel-sar is, as we saw in the phase II study, we see excellent tumor control. 80% of patients who were treated at the therapeutic dose in the phase II study achieved tumor control. 90% of those patients preserved their vision. So, if now there's an option to treat this disease early, stop the tumor from growing, but preserve vision, it really opens up the treatment paradigm to have a lot more patients treated earlier in the disease course.
Mm-hmm. Before we get into your already available data from phase II, it would be a good idea to briefly touch on phase III. What sort of design elements would you point to in your phase III design, and what's the current status of that trial?
Yeah. The phase III CoMpass study is fully enrolled. We completed enrollment on 108 subjects at the end of May of this year. The primary efficacy analysis is at 15 months from the last two enrolled patients' enrollment date. We look at percentage of patients who have tumor control, who have progressed versus ceased tumor growth. There is the 24-month study, so we will continue to follow these patients and look at durability of tumor control as well as vision preservation and overall safety. One of the important elements for enriching for a higher probability of success is, and this is something that was negotiated with the ophthalmology division of the FDA and our Special Protocol Assessment, is that patients on the way in needed to have documented growth. The tumors needed to be actively growing in order for these patients to be enrolled.
What that does is it enriches for a separation of the curves within a 15-month time period. It was a design element that was intended to increase the probability of seeing a signal within a reasonable timeframe. It made the enrollment a bit of a pain to get through, to be frank. Importantly, there are precedent examples with this division of employing these enrichment strategies that set up very stringent inclusion/exclusion criteria, again, to sort of enrich for success in the trial design, that do not translate into a narrow label.
When we look at the overall addressable patient population, we certainly do not expect to be limited to active growth, because as I said earlier, the data show the earlier you treat, the better that these patients do in the long run. But it was an important thing to do to give us the high probability of success that we have on the primary endpoint. We are over 99% powered at 100 subjects to detect a difference in line with the phase II results with the study enrolled as it is.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
